Disclosed herein is the use of trans-4{ 2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl} -N,N-dimethylcarbamoyl-cyclohexylamine and/or salts thereof, particularly hydrochloride, in a therapeutically effective amount in the manufacture of a medicament for the treatment of schizophrenia, wherein the therapeutically effective amount is in the range of from 1.5 to 12mg/day.